Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
iRhythm Technologies Inc Market Cap
Based on ratings from 13 stock analysts, the iRhythm Technologies Inc stock price is expected to increase by 14.5% in 12 months. This is calculated by using the average 12-month stock price forecast for iRhythm Technologies Inc. The lowest target is $79 and the highest is $152. Please note analyst price targets are not guaranteed and could be missed completely.
IRTC is a stock in Healthcare which has been forecasted to be worth $99.5 as an average. On the higher end, the forecast price is $152 USD by William Plovanic from Canaccord Genuity and on the lower end IRTC is forecasted to be $79 by Mike Polark from Baird.
These are the latest 20 analyst ratings of IRTC.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| William Plovanic Canaccord Genuity | Buy | $152 | Maintains | Dec 9, 2024 |
| Nathan Treybeck Wells Fargo | Equal-Weight | $86 | Reinstates | Dec 3, 2024 |
| Mike Polark Baird | Outperform | $79 | Maintains | Nov 1, 2024 |
| David Saxon Needham | Buy | $96 | Maintains | Oct 31, 2024 |
| Richard Newitter Truist Securities | Buy | $95 | Maintains | Oct 22, 2024 |
| Richard Newitter Truist Securities | Buy | $80 | Maintains | Oct 14, 2024 |
| David Roman Goldman Sachs | Neutral | $78 | Initiates | Oct 4, 2024 |
| William Plovanic Canaccord Genuity | Buy | $137 | Maintains | Sep 25, 2024 |
| Joanne Wuensch Citigroup | Buy | $110 | Maintains | Aug 22, 2024 |
| Suraj Kalia Oppenheimer | Outperform | $145 | Maintains | Aug 2, 2024 |
| David Saxon Needham | Buy | $119 | Maintains | Aug 2, 2024 |
| Richard Newitter Truist Securities | Buy | $117 | Reiterates | Aug 2, 2024 |
| Mike Polark Baird | Outperform | $110 | Maintains | Aug 2, 2024 |
| Allen Gong JP Morgan | Overweight | $100 | Maintains | Aug 2, 2024 |
| David Rescott Truist Securities | Buy | $134 | Maintains | Jul 16, 2024 |
| Cecilia Furlong Morgan Stanley | Overweight | $130 | Maintains | Jul 15, 2024 |
| Mike Polark Wolfe Research | Outperform | $115 | Upgrade | Jun 20, 2024 |
| David Saxon Needham | Buy | $138 | Maintains | May 3, 2024 |
| William Plovanic Canaccord Genuity | Buy | $122 | Maintains | May 3, 2024 |
| Allen Gong JP Morgan | Overweight | $133 | Maintains | Feb 23, 2024 |
When did it IPO
2016
Staff Count
2,000
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Quentin S. Blackford
Market Cap
$2.72B
In 2023, IRTC generated $492.7M in revenue, which was a increase of 19.90% from the previous year. This can be seen as a signal that IRTC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 20 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - iRhythm Technologies, Inc. (NASDAQ: IRTC) will participate in the Citi 2024 Global Healthcare Conference, focusing on digital health solutions for disease detection and prevention.
Why It Matters - iRhythm's participation in a major healthcare conference signals potential growth opportunities and increased visibility, which could positively impact investor confidence and stock performance.
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Five new studies on LTCM devices focus on digital engagement, patient satisfaction, arrhythmia patterns, and the economic impact of early detection in diabetes and COPD patients.
Why It Matters - The studies indicate advancements in LTCM devices, potentially driving demand and investment in healthcare technology, impacting market growth and profitability in related sectors.
Tue, 05 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - iRhythm Technologies (NASDAQ: IRTC) will participate in the Wolfe Research 2024 Healthcare Conference, highlighting its focus on digital health solutions for disease management.
Why It Matters - iRhythm's participation in a prominent healthcare conference signals potential visibility and networking opportunities, which could influence investor confidence and stock performance.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - iRhythm Technologies (NASDAQ: IRTC) will hold its Q3 2024 earnings call on October 30, 2024, at 4:30 PM ET, featuring executives and analysts from various financial firms.
Why It Matters - The earnings call provides insights into iRhythm's financial performance and strategic direction, influencing investor sentiment and stock price volatility based on management's commentary and guidance.
Wed, 30 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - iRhythm Technologies, Inc. (NASDAQ: IRTC) reported its financial results for Q3 2024, ending September 30, indicating continued focus on digital health solutions.
Why It Matters - iRhythm Technologies' financial results can indicate its growth potential and market performance, influencing stock prices and investor sentiment in the digital health sector.
Fri, 01 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Bragar Eagel & Squire is investigating iRhythm Technologies, Inc. for potential fiduciary duty breaches related to a class action filed for long-term stockholders covering January 2022 to May 2023.
Why It Matters - The investigation into iRhythm Technologies may indicate potential legal and financial risks, impacting stock performance and investor confidence due to possible breaches of fiduciary duties.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
